<code id='84FA0A7C8D'></code><style id='84FA0A7C8D'></style>
    • <acronym id='84FA0A7C8D'></acronym>
      <center id='84FA0A7C8D'><center id='84FA0A7C8D'><tfoot id='84FA0A7C8D'></tfoot></center><abbr id='84FA0A7C8D'><dir id='84FA0A7C8D'><tfoot id='84FA0A7C8D'></tfoot><noframes id='84FA0A7C8D'>

    • <optgroup id='84FA0A7C8D'><strike id='84FA0A7C8D'><sup id='84FA0A7C8D'></sup></strike><code id='84FA0A7C8D'></code></optgroup>
        1. <b id='84FA0A7C8D'><label id='84FA0A7C8D'><select id='84FA0A7C8D'><dt id='84FA0A7C8D'><span id='84FA0A7C8D'></span></dt></select></label></b><u id='84FA0A7C8D'></u>
          <i id='84FA0A7C8D'><strike id='84FA0A7C8D'><tt id='84FA0A7C8D'><pre id='84FA0A7C8D'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:leisure time    Page View:93949
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          AltruBio raises $225 million to develop ulcerative colitis drug
          AltruBio raises $225 million to develop ulcerative colitis drug

          Micrographofchronicactiveulcerativecolitisinabiopsyspecimen.WikimediaCommonsCheckpointinhibitors,dru

          read more
          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more

          HHS's proposed rule does nothing to address the climate crisis

          MariamZuhaib/APInApril,theU.S.DepartmentofHealthandHumanServices,theworld’smostpowerfulhealthcareage